Cargando…
Subcutaneous Enoxaparin Safely Facilitates Bedside Sustained Low-Efficiency Hemodialysis in Hypercoagulopathic Coronavirus Disease 2019 Patients—A Proof-of-Principle Trial
OBJECTIVES: Renal replacement therapy in coronavirus disease 2019 patients is complicated by increased activation of the coagulation system. This may worsen the quality of hemodialysis and contribute to a shortage of dialysis machines as well as plastic disposables during the pandemic. This study de...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7314355/ https://www.ncbi.nlm.nih.gov/pubmed/32696014 http://dx.doi.org/10.1097/CCE.0000000000000155 |
_version_ | 1783550048785661952 |
---|---|
author | Neumann-Haefelin, Elke Widmeier, Eugen Bansbach, Joachim Kaufmann, Kai Heinrich, Sebastian Walz, Gerd Bürkle, Hartmut Kalbhenn, Johannes |
author_facet | Neumann-Haefelin, Elke Widmeier, Eugen Bansbach, Joachim Kaufmann, Kai Heinrich, Sebastian Walz, Gerd Bürkle, Hartmut Kalbhenn, Johannes |
author_sort | Neumann-Haefelin, Elke |
collection | PubMed |
description | OBJECTIVES: Renal replacement therapy in coronavirus disease 2019 patients is complicated by increased activation of the coagulation system. This may worsen the quality of hemodialysis and contribute to a shortage of dialysis machines as well as plastic disposables during the pandemic. This study describes a simple and safe protocol of anticoagulation with low-molecular-weight heparin in combination with bedside sustained low-efficiency hemodialysis in coronavirus disease 2019 patients. DESIGN: Monocentric observational cross-over trial investigating sustained low-efficiency hemodialysis with unfractionated heparin following sustained low-efficiency hemodialysis with low-molecular-weight heparin. SETTING: Coronavirus disease 2019-ICU in a German Tertiary Care University Hospital. PATIENTS: Three consecutive severe coronavirus disease 2019 patients receiving nine sustained low-efficiency hemodialysis therapies with unfractionated heparin followed by 18 sustained low-efficiency hemodialysis therapies with low-molecular-weight heparin. INTERVENTIONS: Switch from IV unfractionated heparin to subcutaneous low-molecular-weight heparin enoxaparin in therapeutic doses for patients receiving bedside sustained low-efficiency hemodialysis. MEASUREMENTS AND MAIN RESULTS: Nine renal replacement therapy sessions in patients anticoagulated with high doses of unfractionated heparin had to be discontinuated prematurely because of clotting of tubes or membrane and poor quality of hemodialysis. In the same patients, the switch to anticoagulation with therapeutic doses of the low-molecular-weight heparin enoxaparin allowed undisturbed bedside sustained low-efficiency hemodialysis for at least 12 hours. Quality of hemodialysis was excellent, no bleeding event was observed. CONCLUSIONS: Systemic anticoagulation with subcutaneous enoxaparin provides an effective and safe renal replacement procedure in critically ill patients with coronavirus disease 2019 and hypercoagulability. The protocol reduces the risk of filter clotting, blood loss, and poor dialysis quality and may also prevent systemic thromboembolism. |
format | Online Article Text |
id | pubmed-7314355 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-73143552020-06-25 Subcutaneous Enoxaparin Safely Facilitates Bedside Sustained Low-Efficiency Hemodialysis in Hypercoagulopathic Coronavirus Disease 2019 Patients—A Proof-of-Principle Trial Neumann-Haefelin, Elke Widmeier, Eugen Bansbach, Joachim Kaufmann, Kai Heinrich, Sebastian Walz, Gerd Bürkle, Hartmut Kalbhenn, Johannes Crit Care Explor Brief Report OBJECTIVES: Renal replacement therapy in coronavirus disease 2019 patients is complicated by increased activation of the coagulation system. This may worsen the quality of hemodialysis and contribute to a shortage of dialysis machines as well as plastic disposables during the pandemic. This study describes a simple and safe protocol of anticoagulation with low-molecular-weight heparin in combination with bedside sustained low-efficiency hemodialysis in coronavirus disease 2019 patients. DESIGN: Monocentric observational cross-over trial investigating sustained low-efficiency hemodialysis with unfractionated heparin following sustained low-efficiency hemodialysis with low-molecular-weight heparin. SETTING: Coronavirus disease 2019-ICU in a German Tertiary Care University Hospital. PATIENTS: Three consecutive severe coronavirus disease 2019 patients receiving nine sustained low-efficiency hemodialysis therapies with unfractionated heparin followed by 18 sustained low-efficiency hemodialysis therapies with low-molecular-weight heparin. INTERVENTIONS: Switch from IV unfractionated heparin to subcutaneous low-molecular-weight heparin enoxaparin in therapeutic doses for patients receiving bedside sustained low-efficiency hemodialysis. MEASUREMENTS AND MAIN RESULTS: Nine renal replacement therapy sessions in patients anticoagulated with high doses of unfractionated heparin had to be discontinuated prematurely because of clotting of tubes or membrane and poor quality of hemodialysis. In the same patients, the switch to anticoagulation with therapeutic doses of the low-molecular-weight heparin enoxaparin allowed undisturbed bedside sustained low-efficiency hemodialysis for at least 12 hours. Quality of hemodialysis was excellent, no bleeding event was observed. CONCLUSIONS: Systemic anticoagulation with subcutaneous enoxaparin provides an effective and safe renal replacement procedure in critically ill patients with coronavirus disease 2019 and hypercoagulability. The protocol reduces the risk of filter clotting, blood loss, and poor dialysis quality and may also prevent systemic thromboembolism. Wolters Kluwer Health 2020-06-15 /pmc/articles/PMC7314355/ /pubmed/32696014 http://dx.doi.org/10.1097/CCE.0000000000000155 Text en Copyright © 2020 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of the Society of Critical Care Medicine. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (http://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections. |
spellingShingle | Brief Report Neumann-Haefelin, Elke Widmeier, Eugen Bansbach, Joachim Kaufmann, Kai Heinrich, Sebastian Walz, Gerd Bürkle, Hartmut Kalbhenn, Johannes Subcutaneous Enoxaparin Safely Facilitates Bedside Sustained Low-Efficiency Hemodialysis in Hypercoagulopathic Coronavirus Disease 2019 Patients—A Proof-of-Principle Trial |
title | Subcutaneous Enoxaparin Safely Facilitates Bedside Sustained Low-Efficiency Hemodialysis in Hypercoagulopathic Coronavirus Disease 2019 Patients—A Proof-of-Principle Trial |
title_full | Subcutaneous Enoxaparin Safely Facilitates Bedside Sustained Low-Efficiency Hemodialysis in Hypercoagulopathic Coronavirus Disease 2019 Patients—A Proof-of-Principle Trial |
title_fullStr | Subcutaneous Enoxaparin Safely Facilitates Bedside Sustained Low-Efficiency Hemodialysis in Hypercoagulopathic Coronavirus Disease 2019 Patients—A Proof-of-Principle Trial |
title_full_unstemmed | Subcutaneous Enoxaparin Safely Facilitates Bedside Sustained Low-Efficiency Hemodialysis in Hypercoagulopathic Coronavirus Disease 2019 Patients—A Proof-of-Principle Trial |
title_short | Subcutaneous Enoxaparin Safely Facilitates Bedside Sustained Low-Efficiency Hemodialysis in Hypercoagulopathic Coronavirus Disease 2019 Patients—A Proof-of-Principle Trial |
title_sort | subcutaneous enoxaparin safely facilitates bedside sustained low-efficiency hemodialysis in hypercoagulopathic coronavirus disease 2019 patients—a proof-of-principle trial |
topic | Brief Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7314355/ https://www.ncbi.nlm.nih.gov/pubmed/32696014 http://dx.doi.org/10.1097/CCE.0000000000000155 |
work_keys_str_mv | AT neumannhaefelinelke subcutaneousenoxaparinsafelyfacilitatesbedsidesustainedlowefficiencyhemodialysisinhypercoagulopathiccoronavirusdisease2019patientsaproofofprincipletrial AT widmeiereugen subcutaneousenoxaparinsafelyfacilitatesbedsidesustainedlowefficiencyhemodialysisinhypercoagulopathiccoronavirusdisease2019patientsaproofofprincipletrial AT bansbachjoachim subcutaneousenoxaparinsafelyfacilitatesbedsidesustainedlowefficiencyhemodialysisinhypercoagulopathiccoronavirusdisease2019patientsaproofofprincipletrial AT kaufmannkai subcutaneousenoxaparinsafelyfacilitatesbedsidesustainedlowefficiencyhemodialysisinhypercoagulopathiccoronavirusdisease2019patientsaproofofprincipletrial AT heinrichsebastian subcutaneousenoxaparinsafelyfacilitatesbedsidesustainedlowefficiencyhemodialysisinhypercoagulopathiccoronavirusdisease2019patientsaproofofprincipletrial AT walzgerd subcutaneousenoxaparinsafelyfacilitatesbedsidesustainedlowefficiencyhemodialysisinhypercoagulopathiccoronavirusdisease2019patientsaproofofprincipletrial AT burklehartmut subcutaneousenoxaparinsafelyfacilitatesbedsidesustainedlowefficiencyhemodialysisinhypercoagulopathiccoronavirusdisease2019patientsaproofofprincipletrial AT kalbhennjohannes subcutaneousenoxaparinsafelyfacilitatesbedsidesustainedlowefficiencyhemodialysisinhypercoagulopathiccoronavirusdisease2019patientsaproofofprincipletrial |